



Correction

Correction: Ono, S.; Lam, S.; Nagahara, M.; Hoon, D.S.B. Circulating microRNA Biomarkers as Liquid Biopsy for Cancer Patients: Pros and Cons of Current Assays. *J. Clin. Med.* 2015, 4, 1890–1907

Shigeshi Ono, Stella Lam, Makoto Nagahara and Dave S. B. Hoon *

Department of Molecular Oncology, John Wayne Cancer Institute, Providence Saint John's Health Center, 2200 Santa Monica Blvd., Santa Monica, CA 90404, USA; onos@jwci.org (S.O.); lams@jwci.org (S.L.); Nagahara.srg2@tmd.ac.jp (M.N.)

* Correspondence: hoond@jwci.org; Tel.: +1-310-449-5267

Academic Editor: Jane Grant-Kels

Received: 31 August 2016; Accepted: 31 August 2016; Published: 12 September 2016

The authors wish to make the following corrections to this paper [1]:

Table 4. Summary of microarrays for cmiRNA.

Assay	Required Input (ng)	Probe Content
Affymetrix GeneChip miRNA Arrays 4.0	130	miRBase v.20
Agilent oligonucleotides microarrays	100	miRBase v.21
Exiqon miRCURY LNA microRNA arrays	30	miRBase v.19
μParaflo® Microfluidic Biochip Technology	1000	miRBase v.21
3D-Gene®	2000	miRBase v.21

should be replaced with

Table 4. Summary of microarrays for cmiRNA.

Assay	Required Input (ng)	Probe Content
Affymetrix GeneChip miRNA Arrays 4.0	130	miRBase v.20
Agilent oligonucleotides microarrays	100	miRBase v.21
Exiqon miRCURY LNA microRNA arrays	30	miRBase v.19
μParaflo® Microfluidic Biochip Technology	1000	miRBase v.21
3D-Gene®	250	miRBase v.21

The authors apologize for any inconvenience caused to the readers by these changes.

Reference

1. Ono, S.; Lam, S.; Nagahara, M.; Hoon, D.S.B. Circulating microRNA Biomarkers as Liquid Biopsy for Cancer Patients: Pros and Cons of Current Assays. *J. Clin. Med.* **2015**, *4*, 1890–1907. [[CrossRef](#)] [[PubMed](#)]



© 2016 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC-BY) license (<http://creativecommons.org/licenses/by/4.0/>).